Skip to main content

Advertisement

SpringerLink
Log in

Gout and Organ Transplantation

  • CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Acute and chronic gout are common complications following organ transplantation. Risk factors include those shared with the general population (eg, diuretic use) and transplant-specific risk factors (eg, cyclosporine). Clinical features of gout are similar to those seen in the general population, although tophi may be more common. A definitive diagnosis requires demonstration of monosodium urate crystals within synovial fluid or tophi. Treatment is often empiric, although a poor response should prompt joint aspiration to exclude septic arthritis. Corticosteroids are commonly used to treat acute gout due to the adverse profile and drug interactions with NSAIDs and colchicine. Sustained reduction of serum urate (≤6 mg/dL) is critical in long-term management. Allopurinol is the most commonly used agent, although vigilant monitoring is required if combined with azathioprine. Other options include febuxostat and benzbromarone. The role of newer agents such as interleukin-1 inhibitors and uricases remains to be determined. General measures should include minimizing diuretic use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Stamp L, Ha L, Searle M, et al. Gout in renal transplant recipients. Nephrology. 2006;11:367–71.

    Article  PubMed  CAS  Google Scholar 

  2. Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005;65:2593–611.

    Article  PubMed  CAS  Google Scholar 

  3. Cea-Soriano L, Rothenbache D, Choi H, García Rodríguez L. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther. 2011;13:R39.

    Article  PubMed  Google Scholar 

  4. •• Singh J, Reddy S, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheum. 2011;23:192–202. This review highlights the evidence for key risk factors for gout, including dietary factors, alcohol, and medications.

    CAS  Google Scholar 

  5. • Zawiasa A, Szklarek-Kubicka M, Fijałkowska-Morawska J, et al. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. Transplant Proc. 2009;41:188–91. Dietary fructose recently has been recognized as having important effects on SU. This is the only study examining the effects of oral fructose on patients with kidney transplants. It clearly documents a rise in SU with an oral fructose load, with no difference between patients on tacrolimus or cyclosporine.

    Article  PubMed  CAS  Google Scholar 

  6. Barrera Pulido L, Álamo Martínez J, Pareja Ciuró F, et al. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors. Transplant Proc. 2008;40:2985–7.

    Article  PubMed  CAS  Google Scholar 

  7. Urbizu J, Zarraga S, Gomez-Ullate P, et al. Safety and efficacy of tacrolimus rescue therapy in 55 kidney transplant recipients treated with cyclosporin. Transplant Proc. 2003;35:1704–5.

    Article  PubMed  CAS  Google Scholar 

  8. Trück, Laube G, von Vigier R, Goetschel P. Gout in pediatric renal transplant recipients. Pediatr Nephrol. 2010;25:2535–8.

    Article  PubMed  Google Scholar 

  9. Cohen M, Cohen E. Enthesopathy and atypical gouty arthritis following renal transplantation: a case controlled study. Revue du Rheumatisme (English edition). 1995;62:86–90.

    CAS  Google Scholar 

  10. Peeters P, Sennesael J. Low-back pain caused by spinal tophus—a complication of gout in a kidney transplant recipient. Nephrol Dial Transplant. 1998;13:3245–7.

    Article  PubMed  CAS  Google Scholar 

  11. Chan P, Seeger L, Motamedi K, Chan J. Tophaceous gout of the first costochondral junction in a heart transplant patient. Skeletal Radiol. 2006;35:684–6.

    Article  PubMed  Google Scholar 

  12. Weng C, Liu M, Lin L, et al. Rare coexistence of gouty and septic arthritis; a report of 14 cases. Clin Exp Rheumatol. 2009;27:902–6.

    PubMed  Google Scholar 

  13. Baker J, Stonecypher M. Coexistence of oligo-articular gout and Mycobacterium kansasii joint and bursal infection in a patient with an orthotopic heart transplant. Clin Exp Rheumatol. 2009;27:843–5.

    PubMed  CAS  Google Scholar 

  14. Gambaro G, Perazella M. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Int Med. 2003;253:643–52.

    Article  CAS  Google Scholar 

  15. Naesens M, Kuypers D, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508.

    PubMed  CAS  Google Scholar 

  16. Terkeltaub R, Furst D, Bennett K, et al. Colchicine efficacy assessed by time to reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the AGREE trial. Arthritis Rheum. 2010;62:1060–8.

    Article  PubMed  CAS  Google Scholar 

  17. Wallace S, Singer J, Duncan G, et al. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18:264–9.

    PubMed  CAS  Google Scholar 

  18. Wluka A, Ryan P, Miller A, et al. Post-cardiac transplantation gout: incidence and therapeutic complications. J Heart Lung Transplant. 2000;19:951–6.

    Article  PubMed  CAS  Google Scholar 

  19. Ducloux D, Schuller V, Bresson-Vautrin, Chalopin J. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant. 1997;12:2389–92.

    Article  PubMed  CAS  Google Scholar 

  20. Pope R, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007;56:3183–8.

    Article  PubMed  CAS  Google Scholar 

  21. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis. Results of a multicenter, phase II, dose ranging study. Arthritis Rheum. 2010;62:3064–76.

    Article  PubMed  CAS  Google Scholar 

  22. • Wanderer A. Rationale and timeliness for IL-1beta-targeted therapy to reduce allogenic organ injury at procurement and to diminish risk of rejection after transplantation. Clin Transplant. 2010;24:301–11. This review examines the evidence for IL-1 inhibition in patients with kidney transplants and highlights the potential role for IL-1 inhibition in preventing transplant rejection. Although this paper has no reference to gout, it provides background evidence for considering further studies of IL-1 inhibition in transplant recipients with gout.

    Google Scholar 

  23. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol. 2001;28:577–80.

    PubMed  CAS  Google Scholar 

  24. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricaemic therapy. Arthritis Care Res. 2004;51:321–5.

    Article  CAS  Google Scholar 

  25. Navascues R, Gomez E, Rodriguez M, et al. Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricaemia of kidney transplant recipients. Nephron. 2002;91:173–4.

    Article  PubMed  CAS  Google Scholar 

  26. Stevens S, Goldman M. Cyclosporin toxicity associated with allopurinol. South Med J. 1992;85:1265–6.

    Article  PubMed  CAS  Google Scholar 

  27. Perez-Ruiz F, Gomez-Ullate P, Amenabar J, et al. Long-term efficacy of hyperuricaemia treatment in renal transplant recipients. Nephrol Dial Transplant. 2003;18:603–6.

    Article  PubMed  CAS  Google Scholar 

  28. Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47–56.

    Article  PubMed  CAS  Google Scholar 

  29. Dalbeth N, Kumar S, Stamp LK, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol. 2006;33:1646–50.

    PubMed  CAS  Google Scholar 

  30. •• Stamp L, O’Donnell J, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment. Arthritis Rheum. 2011;63:412–21. This study reports the efficacy and safety of treating to target SU in patients with gout. Although transplant recipients were not included, patients with renal impairment were successfully treated with higher-than-CrCL-based doses of allopurinol. Although specific studies in transplant recipients are required, this paper provides evidence for such an approach in this difficult-to-treat group.

    Article  PubMed  CAS  Google Scholar 

  31. Zurcher R, Bock H, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A treated renal transplant patients: a prospective study. Nephrol Dial Transplant. 1994;9:548–51.

    PubMed  CAS  Google Scholar 

  32. Masbernard A, Giudicelli C. Ten years experience with benzbromarone in then management of gout and hyperuricaemia. South African Med J. 1981;59:701–6.

    CAS  Google Scholar 

  33. Lee M-H, Graham G, Williams K, Day R. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interests of patients? Drug Safety. 2008;31:643–65.

    Article  PubMed  CAS  Google Scholar 

  34. Baraf H, Matsumoto A, Maroli A, Waltrip R. Resolution of gouty tophi after 12 weeks of pegloticase treatment. Arthritis Rheum. 2008;58:3632–4.

    Article  PubMed  Google Scholar 

  35. Becker M, Treadwell E, Baraf H, et al. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3 randomised, doubleblind, placebo controlled trials. Arthritis Rheum. 2008;58:S880.

    Google Scholar 

  36. Rozenberg S, Koeger A, Bourgeois P. Urate oxidase for gouty arthritis in cardiac transplant recipients. J Rheumatol. 1993;20:2171.

    PubMed  CAS  Google Scholar 

  37. Ippoliti G, Negri M, Campana C, Vigano M. Urate oxidase in hyperuricaemic heart transplant recipients treated with azathioprine. Transplantation. 1997;63:1370–1.

    Article  PubMed  CAS  Google Scholar 

  38. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339–47.

    PubMed  CAS  Google Scholar 

  39. Milionis H, Kakafika A, Tsouli S, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148:635–40.

    Article  PubMed  CAS  Google Scholar 

  40. Melenovsky V, Malik J, Wichterle D, et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J. 2002;144:e6.

    Article  PubMed  Google Scholar 

  41. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol. 2001;28:2294–7.

    PubMed  CAS  Google Scholar 

  42. Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis. 2003;62:572–5.

    Article  PubMed  CAS  Google Scholar 

  43. Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993–9.

    Article  PubMed  CAS  Google Scholar 

  44. Sugioka N, Takai M, Yoshida K, et al. Effects of plasma uric acid on pharmacokinetics of cyclosporine A in living-related renal transplant recipients and pharmacokinetic study in rats with experimental hyperuricaemia. J Clin Pharm Ther. 2010;35:323–32.

    Article  PubMed  CAS  Google Scholar 

  45. •• Bandukwala F, Huang M, Zaltzman J, et al. Association of uric acid with inflammation, progressive allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009;103:867–71. This study examines the relationship among SU, renal transplant function, and cardiovascular disease in 405 patients. Hyperuricemia (SU >6.1 mg/dL) was negatively correlated with glomerular filtration rate (P<0.0001) and positively associated with diuretic use (P=0.013) and time since transplantation. Importantly, those with hyperuricemia had significantly more cardiovascular events than those with normouricemia (P<0.001).

    Article  PubMed  Google Scholar 

  46. Siu Y-P, Leung K-T, Tong M, Kwan T-H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kid Dis. 2006;47:51–9.

    Article  PubMed  CAS  Google Scholar 

  47. Goicoechea M, de Vinuesa S, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5:1388–93.

    Article  PubMed  CAS  Google Scholar 

  48. Neal D, Tom B, Gimson A, et al. Hyperuricaemia, gout and renal function after liver transplantation. Transplantation. 2001;72:1689–91.

    Article  PubMed  CAS  Google Scholar 

  49. • Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein. Curr Opin Rheum. 2011;23:174–77. This review highlights the evidence linking uric acid and cardiovascular disease in the general population.

    Article  CAS  Google Scholar 

  50. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology. 2009;48:804–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Otago, Christchurch, P.O. Box 4345, Christchurch, 8140, New Zealand

    Lisa K. Stamp

  2. Department of Rheumatology, Immunology, and Allergy, Christchurch Hospital, Private Bag 4710, Christchurch, 8140, New Zealand

    Peter T. Chapman

Authors
  1. Lisa K. Stamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter T. Chapman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa K. Stamp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stamp, L.K., Chapman, P.T. Gout and Organ Transplantation. Curr Rheumatol Rep 14, 165–172 (2012). https://doi.org/10.1007/s11926-012-0235-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-012-0235-9

Keywords

Search

Navigation